GLB-COV2-042

GLB-COV2-042 is an mRNA vaccine candidate developed by GreenLight Biosciences encoding the full-length, nonstabilized SARS-CoV-2 spike protein from the ancestral Wuhan-Hu-1 strain, utilizing unmodified uridine nucleotides encased in lipid nanoparticles (LNP). It induces robust humoral and cellular immune responses, including high titers of binding and neutralizing antibodies against homologous and heterologous SARS-CoV-2 variants (e.g., Alpha, Beta, Omicron), with a Th1-biased T-cell profile, in preclinical rodent models. Demonstrated protection against viral replication, weight loss, and lung pathology in SARS-CoV-2 challenge studies in hamsters, positioning it as a precursor to the advanced pseudouridine-modified GLB-COV2-043 candidate.[2][3]